Commentary: Is CRP ready for use to indicate response or remission with infliximab in Crohn's?

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 8, 2012, Pages 960-961

  Card, T ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB;

CROHN DISEASE; HUMAN; NOTE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE;

EID: 84858770333     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05039.x     Document Type: Note

References (4)

1. Reinisch W, Wang Y, Oddens BJ, Link R,. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease:a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012; 35: 568-76.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
3. Vermeire S, Van Assche G, Rutgeerts P,. C-Reactive protein as a marker for inflammatory bowel diseases. Inflamm Bowel Dis 2004; 10: 661-5.
4. Kiss LS, Szamosi T, Molnar T, et al,. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011; 34: 911-22.